Science Daily·3 min read·medium
New GLP-1 pill delivers up to 12% weight loss in 36 weeks
✦AI Summary
A phase II clinical trial has shown that a new oral small-molecule drug, aleniglipron, can help adults with obesity lose up to 12% of their body weight. This medication offers a potential alternative to current peptide-based injectables like Ozempic.
A new oral approach to GLP-1 treatment helped adults with obesity or overweight lose as much as 12 percent of their body weight over 36 weeks, according to a randomized phase II clinical trial published in Nature Medicine.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in